HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QRA special issue

This article was originally published in The Rose Sheet

Executive Summary

Regulatory Toxicology and Pharmacology journal publishes a special issue on Research Institute for Fragrance Material's Dermal Sensitization Quantitative Risk Assessment (QRA) methodology, according to Nov. 18 release from RIFM. This is the most current and comprehensive publication of the methodology available, RIFM notes. "This new methodology is a major improvement over the former approach because it specifically addresses the elements of exposure-based risk assessment that are unique to the induction of dermal sensitization, while being consistent with the principles of general toxicology risk assessment," says Dr. Anne Marie Api, RIFM VP-human health sciences. Under QRA system, consumer products are grouped into 11 categories based on the level of exposure a consumer can expect from using the product; safe concentration limit is then set for a given fragrance ingredient in each category. RIFM is in talks with European Commission's Scientific Committee on Consumer Products, which has hesitated to embrace QRA (1"The Rose Sheet" Oct. 27, 2008, p. 5). The six articles in the special QRA issue are available through the RIFM Web site

You may also be interested in...

RIFM, European Scientists Work To Iron Out Differences On QRA Methodology

The Research Institute for Fragrance Materials is in talks with industry representatives and European scientific authorities regarding its quantitative risk assessment (QRA) approach to fragrance sensitization, which has been received with varying degrees of enthusiasm

EMA Set To Discuss Safety Of Ranitidine Drugs Soon

Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.

Coronavirus Update: Supercomputing, Regulatory Flexibilities & Coordinating Supply Strategies

In addition to our daily in-depth coverage of key events relating to the COVID-19 pandemic, we’re bringing you a periodic round-up of other developments. This edition covers Europe and other countries.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts